Qiagen

Decent end to 2024

06/02/25 -"Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. While mid-single-digit growth is ..."

PDF page sample
Pages
73
Language
English
Published on
06/02/25
Download
You may also be interested by these reports :
05/10/26
When we last teased on Fresenius (BUY; Germany) in May 2025, the story was about slimming down: shedding Vamed, deconsolidating FMC and working the ...
03/10/26
In addition to our upward revision of estimates (as discussed in the EPS section), the strong momentum in the hearing aids sector, the rebound in ...
28/09/26
Along with the downgrades to our DCF and NAV, we now apply a 10% discount to our peer-based valuation metrics. This reflects S&N’s growth lagging ...
14/09/26
Equity markets ended lower on the week ending September 11 as the renewed surge in energy prices revived inflation concerns and pushed bond yields ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO